SCHEMBL29696289

SCHEMBL29696289

NC(=NO)c1ccc(Nc2ncc(-c3ccc(C(F)(F)F)nn3)o2)cn1

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FLT1 P17948 3/20 0.34
KDR P35968 3/20 0.34
FLT4 P35916 2/20 0.34
FLT3 P36888 4/20 0.34
PRKAB2 O43741 2/20 0.34
SRC P12931 2/20 0.34
PRKAG1 P54619 2/20 0.34
PRKAA2 P54646 2/20 0.34
PRKAA1 Q13131 2/20 0.34
MKNK1 Q9BUB5 2/20 0.34
PRKAG3 Q9UGI9 2/20 0.34
PRKAG2 Q9UGJ0 2/20 0.34
PRKAB1 Q9Y478 2/20 0.34
LCK P06239 1/20 0.34
RPS6KA1 Q15418 1/20 0.34
EPHA2 P29317 1/20 0.33
VCP P55072 3/20 0.33
ALOX5 P09917 1/20 0.32
KIT P10721 1/20 0.31
CDK5 Q00535 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22925555 1.00 FLT1 (0.34) FLT1KDRFLT4FLT3PRKAB2
SCHEMBL28733699 0.87 VCP (0.33) FLT1KDRFLT4FLT3PRKAB2
SCHEMBL22925775 0.87 VCP (0.33) FLT1KDRFLT4FLT3PRKAB2
SCHEMBL22925928 0.84 KMT2A (0.40) FLT1KDRFLT4FLT3VCP
SCHEMBL28733637 0.84 KMT2A (0.40) FLT1KDRFLT4FLT3VCP
SCHEMBL24636935 0.84 FLT1 (0.41) FLT1KDRFLT4FLT3PRKAB2
SCHEMBL22925817 0.84 FLT1 (0.41) FLT1KDRFLT4FLT3PRKAB2
SCHEMBL29696293 0.84 FLT1 (0.41) FLT1KDRFLT4FLT3PRKAB2
SCHEMBL22925740 0.82 ALOX5 (0.39) FLT1KDRFLT4FLT3PRKAB2
SCHEMBL22925766 0.82 ALOX5 (0.39) FLT1KDRFLT4FLT3PRKAB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12448371-B2 Inhibitor compounds Cincera Therapeutics Pty Ltd (AU) 2025-10-21 US claimed
US-20260001870-A1 INHIBITOR COMPOUNDS Cincera Therapeutics Pty Ltd (AU) 2026-01-01 US disclosed
US-12448371-B2 Inhibitor compounds Cincera Therapeutics Pty Ltd (AU) 2025-10-21 US disclosed
EP-4003986-A1 INHIBITOR COMPOUNDS Cincera Therapeutics Pty Ltd (AU) 2022-06-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260001870-A1 INHIBITOR COMPOUNDS CES1, NCEH1, NR1H2 FLT1 2182/4885KDR 3311/4885FLT4 3558/4885
US-12448371-B2 Inhibitor compounds SERPINB1, MMP1, SSB FLT1 2567/4885KDR 3951/4885FLT4 3701/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.